Johnson & Johnson Development Corporation
162
32M
98
3.60
18
0.40
57
- Stages of investment
- Areas of investment
Summary
In 1979 was created Johnson & Johnson Development Corporation, which is appeared as VC. The fund was located in North America if to be more exact in United States. Johnson & Johnson Development Corporation appeared to be a CVC structure as part of the corporation. The main department of described VC is located in the New Brunswick.
Opposing the other organizations, this Johnson & Johnson Development Corporation works on 0 percentage points more the average amount of lead investments. The fund is generally included in 7-12 deals every year. Deals in the range of 10 - 50 millions dollars are the general things for fund. Speaking about the real fund results, this VC is 2 percentage points less often commits exit comparing to other organizations. The important activity for fund was in 2009. Despite it in 2019 the fund had an activity. The average startup value when the investment from Johnson & Johnson Development Corporation is 10-50 millions dollars. The increased amount of exits for fund were in 2014.
The standard case for the fund is to invest in rounds with 5-6 partakers. Despite the Johnson & Johnson Development Corporation, startups are often financed by InterWest Partners, Prism Venture Management, Polaris Partners. The meaningful sponsors for the fund in investment in the same round are Quaker BioVentures, InterWest Partners, Delphi Ventures. In the next rounds fund is usually obtained by Domain Associates, SR One, Medtronic.
This organization was formed by John L. Cassis. The overall number of key employees were 1.
Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has specific favorite in a number of founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. We can highlight the next thriving fund investment areas, such as Medical Device, Biotechnology. Among the various public portfolio startups of the fund, we may underline GRAIL, NovoCure, 23andMe
Investments analytics
Analytics
- Total investments
- 162
- Lead investments
- 18
- Exits
- 57
- Rounds per year
- 3.60
- Follow on index
- 0.40
- Investments by industry
- Health Care (123)
- Biotechnology (113)
- Medical (81)
- Medical Device (58)
- Health Diagnostics (38) Show 43 more
- Investments by region
-
- United States (131)
- Switzerland (7)
- United Kingdom (5)
- Canada (4)
- Denmark (5) Show 5 more
- Peak activity year
- 2009
- Number of Unicorns
- 4
- Number of Decacorns
- 4
- Number of Minotaurs
- 3
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 19
- Avg. valuation at time of investment
- 182M
- Group Appearance index
- 0.96
- Avg. company exit year
- 10
- Avg. multiplicator
- 2.48
- Strategy success index
- 0.90
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
| Company name | Deal date | Industry | Deal stage | Deal size | Location |
|---|---|---|---|---|---|
| Ayannah | 29 Dec 2015 | E-Commerce, Financial Services, FinTech, Payments, Emerging Markets | Early Stage Venture | 3M | Rizal, Pasig, Philippines |
| Binx Health | 18 Jul 2011 | Biotechnology, Mobile, Health Care, Health Diagnostics, Medical Device | Early Stage Venture | 23M | United States, Massachusetts, Boston |
| Osteal Therapeutics | 21 Sep 2023 | Biotechnology, Health Care, Medical Device, Medical, Pharmaceutical | Late Stage Venture | 23M | United States, California, San Clemente |
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.